Pharma innovators will welcome SCOTUS decision to tackle 102 uncertainty; but must wait for 101 guidance 09 Jul 18
The US Supreme Court’s treatment of patentability in recent times has often been frustrating to life sciences innovators, with last month’s refusal to grasp the nettle of patent eligible subject matter in Cleveland Clinic Foundation v True Health Diagnostics being the latest setback. However, the highest court’s recent grant of certiorari in Helsinn Healthcare v Teva Pharmaceutical is a silver lining for inventors in the sector - creating the prospect of greater certainty on the rules surrounding prior art and novelty under Section 102, an issue which is of great importance that has been thrown into confusion by recent developments at the Federal Circuit.
Want to read more?
Register to access two of our subscriber-only articles per month
Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts
What our customers are saying
Very impressed. Clear, usable insights into the business of IP, and particularly awareness of new strategic IP concepts and tools. I also find it effective for helping frame IP issues with clients and benchmarking to IAM best practice examples. Compares well with the LES journal, and both together cover a broad and thorough toolkit for any IP-centric businessperson.
President/IP strategy consultant
Isentient Technologies Corp
Subscribe to receive access to the full range of premium business intelligence, insights and analysis, as well as our IP directories, guides and daily news.
Register for more free content
- Read more IAM blogs and articles
- Receive the editor's weekly review by email